Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 248285
6,715,485 – Nasal delivery device
8,327,844 – Nasal delivery method
7,740,014 – Nasal devices
Product(s) means any products or product candidates developed by or under the authority of a Party or any of its Affiliates as of the Effective Date or during the Term consisting of a formulation that contains [as its sole active ingredient] a compound within the class of compounds [known as triptans], including any salt, polymorphic or amorphous form of such a compound, that is delivered in a nasal delivery device; [provided that, the foregoing definition of Product may be amended and expanded by the mutual agreement of the Parties, in each Partys sole discretion, to include a formulation of triptan with one or more other active ingredients]. For purposes of the foregoing, the class of compounds known as [triptans] includes the compounds known as of the Effective Date as the following Sumatriptan[, rizatriptan, naratriptan, zolmitriptan, almotriptan, frovatriptan, avitriptan and eletriptan]. Solely for the purposes of a Product shall also include products or product candidates consisting of [ a formulation that contains a compound within the class of compounds known as triptans (including any salt, polymorphic or amorphous form of such a compound) together with one or more other active ingredients, that is delivered in a nasal delivery device].
Licensor Trademarks means, any, whether domestic or foreign, trademarks, service marks, and trade names Controlled by Licensor or any of its Affiliates as of the Effective Date or during the Term that are used (or required to be used) in connection with the Device or a Product in the Licensed Territory, including those trademarks, service marks and trade names listed (the 'Existing Licensor Trademarks').
Service marks and trade names
Optimist, Optimose, Breath Powered, Bi-Directional
IPSCIO Record ID: 369286
Licensee has the right to grant sublicenses under the license granted to any Affiliate or Third Party, other than a Licensor Competitor, to commercialize the Product in EU, Japan, Australia, New Zealand, Canada, the United States and/or the Territory in its entirety without Licensorâ€™s prior written approval.
8,337,817 – Preparation for transnasal application
Product means the product consisting of (i) a pharmaceutical product containing the Compound, as the only active pharmaceutical ingredient, formulated using the Formulation Technology and (ii) the Device that contains such pharmaceutical product.
Device means the single-use version of Licensorâ€™s proprietary nasal delivery device (Fit-lizerâ„¢).
Compound means the compound known as Dihydroergotamine or DHE, and any complex, chelate, salt, hydrate, polymorph, isomer, diastereomer, prodrug, congener, metabolite or ion pair thereof.
Formulation Technology means Licensorâ€™s proprietary nasal drug delivery formulation technology as further described below, including its powdery drug carrier (Âµcoâ„¢ System carrier).
– Licensors proprietary inhalable dry powder pharmaceutical formulations designed to enhance drug absorption, comprising of one or more physiologically active substance and muco-adhesive powder drug carrier (Âµcoâ„¢ Carrier) including Microcrystalline cellulose CeolusÂ® PH-F20JP (Manufacturer Asahi Kasei Corporation), microcrystalline cellulose CeolusÂ® PH-301; (Manufacturer Asahi Kasei Corporation) and tribasic calcium phosphate.
TO-2070 is expected to offer a new and potentially improved approach to the treatment of acute migraine. Preclinical data suggest that TO-2070 may offer significant migraine treatment benefits beyond those provided by less convenient and more invasive DHE drug delivery methods, such as injection, liquid nasal sprays or pulmonary inhalation. TO-2070 is designed to provide these benefits at a relatively low cost via a unique and proprietary nasal powder drug delivery system that can be easily self-administered by patients.
TO-2070 is based on a novel nasal powder drug delivery technology created by SNBL that combines a muco-adhesive drug carrier with a proprietary nasal powder drug delivery device. This system is the product of a decade-long SNBL internal development program with the objective of unlocking the significant market potential for nasal drug delivery by overcoming many of the obstacles that have limited its application to date. Unlike previous nasal drug delivery technologies, the SNBL system is able to consistently deliver drug into the nasal cavity with each administration and hold it in place on the nasal mucosa to enable enhanced absorption into the bloodstream. Delivery of the dry powder drug formulation to the nasal mucosa via the specially designed device nozzle is achieved by simply squeezing the device.
IPSCIO Record ID: 294022
Licensor Developed Technology shall mean improvements to the Licesor Know-How and Licensor Patents conceived, created, developed or otherwise invented or acquired solely by an employee or agent of Licensor or one of its Affiliates or a Third Party (under contract with Licensor or one of its Affiliates) as a direct result of fulfilling obligations or exercising rights, including the sharing of Confidential Information, under this Agreement or any other agreement between the Parties.
Licensor Patents shall mean any and all rights under the Patent Applications and/or Patents as set forth as of the Effective Date and as amended from time to time, and any foreign counterparts thereof and all divisionals, continuations, continuations-in-part, any foreign counterparts thereof and all patents issuing on any of the foregoing, and any foreign counterparts thereof, together with all registrations, reissues, re-examinations, supplemental protection certificates, or extensions thereof, and any foreign counterparts thereof. In the event any additional Licensor Patent or Patent Application is necessary or useful to allow Licensee to practice the rights granted to it by Licensor herein, Licensor shall include such Patent or Patent Application as applicable.
US application 10/497715 – Method of Particle Formation
US application 10/017135 – Synthesis of small particles.
Compound shall mean (i) any beta-agonist in combination with any steroid; (ii) any steroid; and (iii) insulin, as well as any salts, isomorphs, polymorphs, cogeners or isomers of the preceding. Initial specifications for each Compound will be agreed to by the parties and after such agreement shall be considered an original part of this Agreement.
Product shall mean the Formulation comprising the Product Intermediate and, to the extent required to effect delivery to a patient, a delivery device for use in the Field.
Formulation shall mean a composition of Product Intermediate suitable for administration by inhalation via pulmonary or nasal delivery, as applicable. A Formulation may comprise a mixture, blend or solution of the Product Intermediate combined with excipients and/or adjuvants or neat Product Intermediate and a single Product Intermediate may be covered by more than one Formulation. Specifications for each Formulation will be developed by MAP and after such development shall be considered an original part of this Agreement.
Beta-agonist shall mean any short-acting beta-agonist or any long-acting beta agonist as those terms may be further defined from time to time in a generally accepted pharmacology textbook.
Licensee is engaged in the research and development of proprietary drug delivery systems for inhalation therapy by pulmonary or nasal delivery, including devices and formulations suitable for those devices.
IPSCIO Record ID: 32979
â€œNO Gasâ€ means nitric oxide gas.
â€œNO Gas Containerâ€ means a storage vessel for NO Gas.
â€œNO Gas Delivery Device(s)â€ means devices used for the delivery of NO Gas that contain Intellectual Property Licensed by CareFusion to Licensee.
Nitric Oxide (NO) possesses broad-spectrum anti-microbial activity acting against bacteria, fungi and viruses. NO is produced at high output as part of the innate immune response. NO and its by-products (for example, Reactive Nitrogen Species, RNS) are responsible for the process of killing microorganisms within white blood cells called macrophages and in organs such as the lungs and other mucolytic tissues.
IPSCIO Record ID: 240465
(i) an exclusive license of the Licensor Intellectual Property and the Joint Intellectual Property in connection with the applications or deliveries of compounds listed, except with respect to any Retained Licensor Intellectual Property, as to which Licensee is being granted a non-exclusive license
(ii) a non-exclusive license of the Licensor Intellectual Property and the Joint Intellectual Property in connection with the applications or deliveries of compounds listed on Appendix E, and
(iii) subject to existing contractual rights of third parties, an exclusive license of the Licensor Intellectual Property and the Joint Intellectual Property for use with any other compounds not listed on Appendices D or E and which are not Licensor Compounds.
In each case for use only as Auto-Injector Technology and in the Field for the Territory to develop, make, have made, manufacture, have manufactured, package, use, import, export, promote, distribute, market, offer for sale, and sell the Devices and Products in the Field for the Territory.
Auto-Injector Technology shall mean any technology incorporated or used in a device (i) constituting a disposable, single use, needle injection system wherein the active ingredient is housed in a vial which is situated in a manner substantially perpendicular to the body surface, (ii) utilizing gas generation achieved via a chemical reaction for delivery of the active ingredient and (iii) having infusion time for delivery of an active ingredient which is less than or equal to 10 seconds. For the avoidance of doubt, Auto-Injector Technology shall not include any other technology that does not meet the foregoing definition, whether or not similar or containing elements of the Licensor Intellectual Property, including, without limitation, the Medipad(TM) Technology or any other Excluded Technology.